At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Closed New Year's Day 12-31 16:00:00 EST
582.34
-1.39
-0.24%
盘后582.34
+0.000.00%
19:13 EST
High592.72Low581.52Vol155.81K
Open583.21D1 Closing583.73Amplitude1.92%
Mkt Cap13.23BTradable Cap6.41BTotal Shares22.71M
T/O91.22MT/O Rate1.42%Tradable Shares11.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Madrigal Pharmaceuticals (MDGL) Is Up 5.4% After REZDIFFRA Phase 3 Data And CFO Hire - Has The Bull Case Changed?
Simply Wall St.  ·  2025-12-23
Madrigal Pharmaceuticals (MDGL) Is Up 5.4% After REZDIFFRA Phase 3 Data And CFO Hire - Has The Bull Case Changed?
Madrigal Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Dow Jones  ·  2025-12-19
Madrigal Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Madrigal Pharmaceuticals Inc : Piper Sandler Raises Target Price to $900 From $540
THOMSON REUTERS  ·  2025-12-19
Madrigal Pharmaceuticals Inc : Piper Sandler Raises Target Price to $900 From $540
Madrigal Pharmaceuticals Grants Equity Awards to New Employees
Reuters  ·  2025-12-19
Madrigal Pharmaceuticals Grants Equity Awards to New Employees
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  2025-12-19
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Madrigal Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $581 From $456
THOMSON REUTERS  ·  2025-12-16
Madrigal Pharmaceuticals Inc : Bofa Global Research Raises Price Objective to $581 From $456
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire  ·  2025-12-16
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals Director Paul A. Friedman Reports Sale of Common Shares
Reuters  ·  2025-12-13
Madrigal Pharmaceuticals Director Paul A. Friedman Reports Sale of Common Shares
Director Rebecca Taub Reports Disposal of Madrigal Pharmaceuticals Common Shares
Reuters  ·  2025-12-13
Director Rebecca Taub Reports Disposal of Madrigal Pharmaceuticals Common Shares
Madrigal Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Dow Jones  ·  2025-12-12
Madrigal Pharmaceuticals Is Maintained at Buy by B. Riley Securities
Madrigal Pharmaceuticals Inc : B. Riley Raises Target Price to $670 From $560
THOMSON REUTERS  ·  2025-12-11
Madrigal Pharmaceuticals Inc : B. Riley Raises Target Price to $670 From $560
B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating
MT Newswires Live  ·  2025-12-11
B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  2025-12-05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Reuters  ·  2025-12-04
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares
Reuters  ·  2025-12-04
Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares
Madrigal Pharmaceuticals CCO Makes a Significant Stock Sale!
TIPRANKS  ·  2025-11-22
Madrigal Pharmaceuticals CCO Makes a Significant Stock Sale!
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman Reports Disposal of Common Shares
Reuters  ·  2025-11-22
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman Reports Disposal of Common Shares
Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  2025-11-22
Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra
TIPRANKS  ·  2025-11-22
Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra
Madrigal price target raised to $620 from $568 at H.C. Wainwright
TIPRANKS  ·  2025-11-22
Madrigal price target raised to $620 from $568 at H.C. Wainwright

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--